Sara Khaksar

Guildford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Net survival of men with localized prostate cancer after LDR brachytherapy.

Net survival of men with localized prostate cancer after LDR brachytherapy.

Journal: Brachytherapy
Published: May 18, 2023

Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?

Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?

Journal: Brachytherapy
Published: April 27, 2022

Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience.

Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience.

Journal: BJU international
Published: May 04, 2021

In Regard to Parry et al.

In Regard to Parry et al.

Journal: International journal of radiation oncology, biology, physics
Published: January 19, 2021

Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.

Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.

Journal: BJU international
Published: October 08, 2020

Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure.

Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure.

Journal: BJUI compass
Published: August 20, 2020

Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach.

Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: March 13, 2020

Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer.

Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer.

Journal: BJU international
Published: November 10, 2019

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Journal: Lancet (London, England)
Published: September 18, 2018

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.

Journal: BMC cancer
Published: August 30, 2018

Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.

Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.

Journal: BJU international
Published: April 03, 2018

Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.

Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.

Journal: BJU international
Published: July 04, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026